Dose-ranging Study to Evaluate Antibody Response to G17DT in Patients With Gastric Cancer

NCT02521649 · clinicaltrials.gov ↗

PHASE2

Phase

COMPLETED

Status

52

Enrollment

INDUSTRY

Sponsor class

Conditions

Gastric Cancer

Interventions

DRUG: G17DT

Sponsor

Cancer Advances Inc.

Collaborators

[object Object]
[object Object]